ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 152

Characteristics of Patients With Juvenile Idiopathic Arthritis in a US Healthcare Claims Database

TA Simon1, A Baheti2, N Ray2, S Kelly1 and Z Guo1, 1Bristol-Myers Squibb, Princeton, NJ, 2Mu Sigma, Bangalore, India

Meeting: 2017 Pediatric Rheumatology Symposium

Keywords: Abatacept, autoimmune diseases, DMARDs, juvenile idiopathic arthritis (JIA) and patient

  • Tweet
  • Email
  • Print
Session Information

Date: Thursday, May 18, 2017

Session Title: Quality, Health Services and Education Research Poster Session

Session Type: Abstract Submissions

Session Time: 5:30PM-7:00PM

Background/Purpose: Abatacept, the first selective co-stimulation modulator approved and used for the treatment of juvenile idiopathic arthritis (JIA), has a mechanism of action that is fundamentally different from that of other biologic (b)DMARDs. The purpose of this study was to describe the baseline characteristics of patients with a diagnosis of JIA in a US healthcare claims (HCC) database treated with abatacept and those treated with other bDMARDs.

Methods: Patients <18 years of age and diagnosed with JIA in the Truven Health MarketScan® database between July 1 2006 and September 30 2014 were eligible for inclusion in the analysis. Patients were required to have at least 180 days of continuous health plan enrollment prior to, and ≥1 day following, a diagnosis of JIA based on two International Classification of Diseases, Ninth Revision, Clinical Modification codes (714.3x) within 90 days. The abatacept cohort includes patients initiating abatacept or another bDMARD who may be initiating a biologic for the first time or switching from one biologic to another. Baseline characteristics including at least 15 co-morbid conditions and concomitant medications were captured within the 6-month period prior to the diagnosis of JIA. Results: A total of 13,602 patients with a diagnosis of JIA were identified in the US HCC database, with an average follow-up of 2.26 years (maximum 8.26 years); 343 abatacept users and 3507 users of other bDMARDs were identified. Overall, abatacept users were slightly older and more likely to have asthma and hypertension; other bDMARDs users were more likely to have uveitis reported in the 6-month baseline period. Corticosteroid use and outpatient visits were also higher in abatacept users.

JIA patients

N=13,602

n (%)

Abatacept-treated patients

n=343

n (%)

Other biologic-treated patients

n=3507

n (%)

Female, n (%)

9679 (71.2)

284 (82.8)***

2563 (73.1)

Age, mean (SD)

10.4 (4.6)

12.0 (3.8)

11.2 (4.4)

Asthma, n (%)

873 (6.4)

28 (8.2)*

187 (5.3)

Cardiovascular disease, n (%)

618 (4.5)

24 (7.0)

171 (4.9)

Hypertension, n (%)

83 (0.6)

8 (2.3)*

27 (0.8)

Uveitis, n (%)

1302 (9.6)

32 (9.3)

467 (13.3)*

Biologic DMARDs, n (%)

1732 (12.7)

168 (49.0)

1564 (44.6)

Non-biologic DMARDs, n (%)†

3321 (24.4)

156 (45.5)

1548 (44.1)

MTX, n (%)

2798 (20.6)

125 (36.4)

1382 (39.4)

IV antibiotics, n (%)

366 (2.7)

11 (3.2)

100 (2.9)

Corticosteroids, n (%)‡

1789 (13.2)

93 (27.1)**

731 (20.8)

NSAIDs, n (%)

5151 (37.9)

145 (42.3)

1551 (44.2)

Inpatient visits, mean (SD)

0.08 (0.36)

0.10 (0.45)

0.09 (0.38)

Outpatient visits, mean (SD)

8.70 (7.81)

11.66 (10.41)***

9.60 (8.54)

*p<0.05; **p<0.01; ***p≤0.0001 for the difference between abatacept-treated

patients and other biologic-treated patients. †Non-biologic DMARDs included

hydroxychloroquine, sulfasalazine, leflunomide, and cyclosporine;

‡Corticosteroids consist of prednisolone, methylprednisolone,

triamcinolone, prednisone, dexamethasone, budesonide, and

betamethasone

  Conclusion: In this analysis, patients with JIA who were treated with abatacept were older and more likely to have asthma and hypertension than patients treated with other bDMARDs. The patients with JIA treated with abatacept in this US HCC database were slightly younger, with less uveitis at baseline, compared with a population of abatacept-treated patients in a worldwide JIA registry (mean age 13 years and 15% history of uveitis).1,2

References:

1.    Lovell DJ, et al. ACR/ARHP Annual Scientific Meeting, 2015. Poster 1446. 2.    Abstract reprinted from the PreS 2016 Annual Meeting held September 27–October 1, 2016. The Paediatric Rheumatology European Society does not guarantee, warrant, or endorse any commercial products or services. Reprinted by Bristol-Myers Squibb.  


Disclosure: T. Simon, 1,3; A. Baheti, 5; N. Ray, 5; S. Kelly, 1,3; Z. Guo, 1,3.

To cite this abstract in AMA style:

Simon T, Baheti A, Ray N, Kelly S, Guo Z. Characteristics of Patients With Juvenile Idiopathic Arthritis in a US Healthcare Claims Database [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 4). https://acrabstracts.org/abstract/characteristics-of-patients-with-juvenile-idiopathic-arthritis-in-a-us-healthcare-claims-database/. Accessed February 4, 2023.
  • Tweet
  • Email
  • Print

« Back to 2017 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characteristics-of-patients-with-juvenile-idiopathic-arthritis-in-a-us-healthcare-claims-database/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences